Ultragenyx Pharmaceutical Inc. released its 2025 Impact Report on July 08, 2026, detailing the company's advancements in rare and ultra-rare disease therapies and its corporate responsibility efforts. The report highlights progress across six key pillars: Innovation, Patients, People, Communities, Planet, and Governance. It covers activities from January 1 through December 31, 2025, and includes indices from the Sustainability Accounting Standards Board (SASB), Global Reporting Initiative (GRI), and Task Force on Climate Related Disclosures (TCFD).

Innovation and R&D Investment

Ultragenyx focused on addressing significant unmet medical needs for rare disease patients. The company advanced five clinical-stage investigational therapies with the potential to reach tens of thousands of patients. It applied its Dynamic Development Model (DDM), centered around direct patient and caregiver input, to inform clinical trial design and accelerate development across 160+ clinical trial sites in 19 countries.

Patient Access and Advocacy

The company expanded access to its four approved therapies across five indications. It supported more than 700 patients in 50 countries through expanded access and patient assistance programs since 2013. In 2025, Ultragenyx participated in over 45 global patient advocacy events and launched Act for Ultra-Rare to advocate for legislation supporting ultra-rare disease treatments.

Workforce and Community Engagement

Ultragenyx maintained strong employee engagement with an overall score of 86% and delivered more than 80 employee learning and development workshops. The company approved approximately $3.3 million in charitable donations, medical education, and health-related grants across more than 20 countries. Employees contributed over 2,800 volunteer hours supporting local and global initiatives.

Environmental and Governance Highlights

Ultragenyx purchased ~100% renewable electricity for its Novato, CA headquarters and Bedford, MA facility. It initiated its second My Green Lab certification in Somerville, MA and conducted its inaugural Climate Risk Assessment. The company reported no material data privacy breaches or cybersecurity incidents in 2025 and maintained a comprehensive compliance program aligned with global regulatory standards.

RBC Capital analyst Luca Issi has maintained an Outperform rating on Ultragenyx Pharmaceutical and raised the price target to $40 from $35. The adjustment reflects a revised valuation outlook for the NASDAQ-listed company.

Rating and Target Details

The research note reinforces a positive stance on Ultragenyx Pharmaceutical, trading under the ticker RARE. The new price target of $40 represents an increase over the prior target of $35.